These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 30582225)

  • 21. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
    Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
    Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
    Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL
    Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.
    Qi L; Bart J; Tan LP; Platteel I; Sluis Tv; Huitema S; Harms G; Fu L; Hollema H; Berg Av
    BMC Cancer; 2009 May; 9():163. PubMed ID: 19473551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Tan X; Li Z; Ren S; Rezaei K; Pan Q; Goldstein AT; Macri CJ; Cao D; Brem RF; Fu SW
    Breast Cancer Res; 2019 Aug; 21(1):89. PubMed ID: 31391072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.
    Li Q; Yao Y; Eades G; Liu Z; Zhang Y; Zhou Q
    Oncogene; 2014 May; 33(20):2589-600. PubMed ID: 23752191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
    Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB
    J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA Expression Profile in Early-Stage Breast Cancers.
    Patel K; Rao DM; Sundersingh S; Velusami S; Rajkumar T; Nair B; Pandey A; Chatterjee A; Mani S; Gowda H
    Microrna; 2024; 13(1):71-81. PubMed ID: 37873952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
    Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
    Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.